EP3856195A4 - METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS - Google Patents

METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS Download PDF

Info

Publication number
EP3856195A4
EP3856195A4 EP19867321.2A EP19867321A EP3856195A4 EP 3856195 A4 EP3856195 A4 EP 3856195A4 EP 19867321 A EP19867321 A EP 19867321A EP 3856195 A4 EP3856195 A4 EP 3856195A4
Authority
EP
European Patent Office
Prior art keywords
aging
compositions
methods
disorders related
treating disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19867321.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3856195A1 (en
Inventor
Steven P. Braithwaite
S. Sakura Minami
Karoly Nikolich
Sanket V. Rege
Arnaud E.J. TEICHERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkahest Inc
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of EP3856195A1 publication Critical patent/EP3856195A1/en
Publication of EP3856195A4 publication Critical patent/EP3856195A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19867321.2A 2018-09-26 2019-09-25 METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS Pending EP3856195A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862737017P 2018-09-26 2018-09-26
PCT/US2019/052995 WO2020069008A1 (en) 2018-09-26 2019-09-25 Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Publications (2)

Publication Number Publication Date
EP3856195A1 EP3856195A1 (en) 2021-08-04
EP3856195A4 true EP3856195A4 (en) 2022-06-22

Family

ID=69953286

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19867321.2A Pending EP3856195A4 (en) 2018-09-26 2019-09-25 METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS

Country Status (15)

Country Link
EP (1) EP3856195A4 (https=)
JP (2) JP7528065B2 (https=)
KR (1) KR20210065950A (https=)
CN (1) CN112789044A (https=)
AU (1) AU2019346456A1 (https=)
BR (1) BR112021004938A2 (https=)
CL (1) CL2021000724A1 (https=)
CO (1) CO2021003713A2 (https=)
EA (1) EA202190463A1 (https=)
IL (1) IL281578A (https=)
MA (1) MA53743A (https=)
MX (1) MX2021002967A (https=)
SG (1) SG11202102105VA (https=)
TW (1) TW202027752A (https=)
WO (1) WO2020069008A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113689A1 (en) 2018-09-25 2020-04-02 Antabio Sas Indane derivatives for use in the treatment of bacterial infection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090330A1 (en) * 2004-03-22 2005-09-29 Astrazeneca Ab N-piperidine derivates as ccr3 modulators
US20130266646A1 (en) * 2012-04-04 2013-10-10 Boehringer Ingelheim International Gmbh Pharmaceutical formulations comprising ccr3 antagonists
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
WO2018187473A1 (en) * 2017-04-05 2018-10-11 Alkahest Inc. Methods and compositions for treating retina-associated disease using ccr3-inhibitors
WO2018187503A1 (en) * 2017-04-05 2018-10-11 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1996551A2 (en) * 2006-03-07 2008-12-03 AstraZeneca AB Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
MX2011011080A (es) 2009-04-22 2012-02-23 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida.
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090330A1 (en) * 2004-03-22 2005-09-29 Astrazeneca Ab N-piperidine derivates as ccr3 modulators
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US20130266646A1 (en) * 2012-04-04 2013-10-10 Boehringer Ingelheim International Gmbh Pharmaceutical formulations comprising ccr3 antagonists
WO2018187473A1 (en) * 2017-04-05 2018-10-11 Alkahest Inc. Methods and compositions for treating retina-associated disease using ccr3-inhibitors
WO2018187503A1 (en) * 2017-04-05 2018-10-11 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
REGE S ET AL: "Abstracts from the 13th International Conference on Cerebral Vascular Biology (CVB 2019)", FLUIDS AND BARRIERS OF THE CNS, vol. 16, no. S1, 1 June 2019 (2019-06-01), XP093106172, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s12987-019-0135-8/fulltext.html> DOI: 10.1186/s12987-019-0135-8 *
See also references of WO2020069008A1 *

Also Published As

Publication number Publication date
BR112021004938A2 (pt) 2021-06-01
JP7528065B2 (ja) 2024-08-05
MA53743A (fr) 2022-01-05
TW202027752A (zh) 2020-08-01
CO2021003713A2 (es) 2021-04-08
AU2019346456A1 (en) 2021-04-15
KR20210065950A (ko) 2021-06-04
JP2024153742A (ja) 2024-10-29
CN112789044A (zh) 2021-05-11
EA202190463A1 (ru) 2021-06-29
CL2021000724A1 (es) 2021-10-15
SG11202102105VA (en) 2021-04-29
MX2021002967A (es) 2021-08-11
IL281578A (en) 2021-05-31
JP2022502441A (ja) 2022-01-11
CA3111433A1 (en) 2020-04-02
EP3856195A1 (en) 2021-08-04
WO2020069008A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
EP2352517A4 (en) METHOD AND COMPOSITIONS FOR TREATING COMPLEMENT ASSOCIATED ILLNESSES
MA54874A (fr) Compositions et procédés de traitement des troubles neurocognitifs
EP3793566A4 (en) COMPOSITIONS AND METHODS FOR REDUCING SPLICEOPATHY AND TREATMENT OF RNA DOMINANCE DISORDERS
EP3973047A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIVER DISEASES
MA54880A (fr) Compositions et procédés de traitement de troubles neurocognitifs
EP3813793A4 (en) COMPOSITION FOR THE TREATMENT OF OCULAR HYPEREMIA AND METHODS FOR TREATMENT OF OCULAR HYPEREMIA THEREFORE
EP3490366A4 (en) METHOD AND COMPOSITIONS FOR GENE EXPRESSION IN PLANTS
EP3969597A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATPASE-MEDIATED DISEASES
EP3826468A4 (en) COMPOSITIONS AND RELATED PROCEDURES FOR AGRICULTURE
EP3368080A4 (en) TREATMENT OF DISEASES OF THE NERVOUS SYSTEM USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES
EP3793562A4 (en) METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE
MA53234A (fr) Compositions et procédés d&#39;inhibition de masp-2 pour le traitement de divers troubles et maladies thrombotiques
EP4045046A4 (en) Methods and compositions for treating iron disorders
EP3701048A4 (en) PROCEDURES AND COMPOSITIONS FOR EVALUATION AND TREATMENT OF INTRAOCULAR DISEASES AND DISORDERS
EP2453743A4 (en) N-ACETYL-CYSTEIN COMPOSITIONS AND METHODS FOR IMPROVED THERAPEUTIC EFFECT OF ACETAMINOPHES
EP4058062A4 (en) Compositions and methods for immunotherapy
EP3737367A4 (en) METHOD OF TREATMENT OF SOLID TUMORS WITH CCR2 ANTAGONISTS
EP3969041A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
EP4110461A4 (en) COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH
EP3801577A4 (en) METHOD AND COMPOSITIONS USING TANKYRASE INHIBITOR FOR GENERATING INSULIN-PRODUCING CELLS
EP3661492A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF NERVOUS DISORDERS
EP3856195A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS
EP3857224A4 (en) PROCEDURES AND COMPOSITIONS FOR THE REMOVAL OF BIOTIN INTERFERENCE FROM ASSAYS WITH MOLECULAR TRAPS
EP4031567A4 (en) METHODS AND COMPOSITIONS FOR TISSUE REGENERATION
EP3946380A4 (en) COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210325

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAV Requested validation state of the european patent: fee paid

Extension state: MD

Effective date: 20210325

Extension state: MA

Effective date: 20210325

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031535000

Ipc: A61K0031454500

A4 Supplementary search report drawn up and despatched

Effective date: 20220520

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20220516BHEP

Ipc: A61P 25/16 20060101ALI20220516BHEP

Ipc: A61P 25/00 20060101ALI20220516BHEP

Ipc: A61K 9/00 20060101ALI20220516BHEP

Ipc: A61K 47/00 20060101ALI20220516BHEP

Ipc: A61K 33/00 20060101ALI20220516BHEP

Ipc: A61K 31/00 20060101ALI20220516BHEP

Ipc: A61P 1/00 20060101ALI20220516BHEP

Ipc: A61K 31/4545 20060101AFI20220516BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231201

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: UPC_APP_0002262_3856195/2026

Effective date: 20260121